1. Fareed J, Kumar A, Walenga JM, Emanuele RM, Williamson K, Hoppensteadt D.Antithrombotic actions and pharmacokinetics of heparin fractions and fragments. Nouv Rev Fr Hematol1984;26:267-267.
2.
2. Fareed J, Walenga JM, Racanelli A, Hoppensteadt D, Huan X, Messmore HL. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. Haemostasis1988;18(Suppl 3):33-33.
3.
3. Barrett JS, Hainer JW, Kornhauser DM, et al. Anticoagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers. Thromb Res2001;101:243-243.
4.
4. Fareed J, Haas S, Sasahara A, eds. Differentiation of low molecular weight heparins. Applied and clinical considerations. Semin Thromb Hemost1999;25(3):17-17.
5.
5. Fareed J, Walenga JM, Hoppensteadt D, Huan X, Racanelli A.Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis1988;18(Suppl 3):3-3.
6.
6. Fareed J, Walenga JM, Williamson K, Emanuele RM, Kumar A, Hoppensteadt D.Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. Semin Thromb Hemost1985;11 (1):56-56.
7.
7. Memorandum on a provisional International Standard for heparin. Bull WHO1942;151-151.
8.
8. Barrowcliffe TW, Curtiss AD, Johnson EA, Thomas DP.An internatiuonal standard for low molecular weight heparin. Thromb Haemost1988;60:1-1.
9.
9. Mulloy B, Gee C, Wheeler SF, Wait R, Gray E, Barrowcliffe TW.Molecular weight measurements of low molecular weight heparins by gel permeation chromatography. Thromb Haemost1997;77(4):668-668.
